Taken together, our findings provide a step towards identifying MRS biomarkers that may potentially be used to monitor response to combination therapy of PI3K pathway inhibition with TMZ during clinical trials in children with glioblastoma. This evidence concerns the gene PIK3CA and glioblastoma.